TRIAL DETAIL
Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 05/01/2008 |
Age of Trial (yrs) 16 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor + mTOR Inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CDR00005953
MDA-2007-0595 |
|||
Sponsor: |
M.D. Anderson Cancer Center
National Cancer Institute (NCI) |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
RATIONALE: Monoclonal antibodies, such as IMC-A12, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving monoclonal antibody IMC-A12 together with temsirolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of monoclonal antibody IMC-A12 and temsirolimus in treating patients with locally advanced or metastatic cancer. |
|||
Trial Links |
Trial Results |
Drug Information |
| CCI-779 (temsirolimus) in Wikipedia |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |